Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Launch of the Gustave Roussy Prize to honor scientific innovation in oncology
On
Villejuif, November 20, 2024
Launch of the Gustave Roussy Prize to honor scientific innovation in oncology
To mark the 150th anniversary of its founder’s birth and the upcoming centennial of the Institute that bears his name, Gustave Roussy is proud to announce the launch of the Gustave Roussy Prize. This exceptional annual award aims to recognize a researcher whose scientific discoveries have significantly impacted cancer patient care.
A visionary physician and renowned scientist, Professor Gustave Roussy revolutionized cancer care by establishing the first consultation dedicated to cancer patients in 1921. The newly launched Gustave Roussy Prize embodies the commitment of the Institute he founded, now focused on personalized approaches to better prevent, challenge prognoses, reduce side effects, and enhance the quality and length of life for every patient.
Supported by Pierre Fabre Laboratories as founding sponsor, the Gustave Roussy Prize is endowed with €200,000 annually. It will honor a leading figure in oncology research whose discoveries have significantly improved cancer patient care. This award ranks among the most generous distinctions worldwide in the field of cancer research.
“We are very proud to support this new prize. We are committed to encouraging Gustave Roussy’s initiatives as Europe’s leading cancer center, recognized for its multidisciplinary expertise and aligned with our purpose: every time we care for a single person, we make the world better. This award also extends the numerous development collaborations we have shared with Gustave Roussy over the past 25 years,” says Éric Ducournau, CEO of Pierre Fabre Laboratories.
“The Gustave Roussy Prize embodies our unwavering commitment to scientific innovation, which is essential to pushing the boundaries of oncology and offering patients increasingly effective and personalized treatments. By honoring researchers whose discoveries transform the lives of patients, we celebrate the forward-thinking vision of our founder and reaffirm our determination to cure cancer in the 21st century,” ads Professor Fabrice Barlesi, CEO of Gustave Roussy.
An Award Aligned with Contemporary Medical Challenges
The Gustave Roussy Prize is designed to honor individuals behind scientific breakthroughs with tangible benefits for cancer patients. It is open to internationally renowned researchers whose work significantly advances the treatment, understanding, or prevention of cancers.
For this inaugural edition of the Gustave Roussy Prize, applications must be submitted by December 20, 2024, at the following link: https://forms.office.com/e/rBSaqphxwG.
Award Ceremony on February 4, 2025
The winner will be selected by a jury of international experts, independent of Gustave Roussy, who will evaluate the applications based on the impact of the researcher’s work on patients. For this first edition, the Gustave Roussy Prize ceremony will be held on February 4, 2025, coinciding with World Cancer Day.
This prestigious award reflects the Institute’s dedication and the enduring vision of Professor Gustave Roussy by placing research at the service of patients and encouraging researchers to continue their vital efforts in the fight against cancer.
pr-gustave-roussy-prize-201124.pdf
Press contact
If you are a journalist and have a question, please contact:
Claire Parisel or Léona Pinto
Tel. +33 1 42 11 50 59
Tel. +33 1 42 11 63 59
Mob. +33 6 17 66 00 26
Email
The Media Team cannot respond to patient inquiries.
Last press releases
-
ESMO 2026 - Addressing the side effects of endocrine therapy: a new care pathway combining digital support and human expertise
Dr Maria Alice Franzoi, medical oncologist and specialist in digital health and care pathway implementation, will present the results of the HOPE study at the ESMO Congress. This clinical trial evaluated a hybrid care pathway combining a mobile application and nurse-led support to help women receiving endocrine therapy for breast cancer. The aim is to reduce the burden of treatment-related side effects, which can compromise adherence to a therapy that is essential for lowering the risk of recurrence, while strengthening patients’ confidence in managing their symptoms. Ultimately, this approach seeks to improve quality of life, access to supportive care, and long-term continuation of endocrine therapy.
-
ESMO 2026 - Exploring the potential of immunotherapy in early-stage triple-negative breast cancer
Dr Joana Ribeiro, medical oncologist in the Drug Development Department at Gustave Roussy, will present the results of the POP-DURVA clinical trial at the ESMO Congress. Conducted within UNLOCK, a flagship programme of the PRISM Institute, the study evaluated the addition of two immunotherapy injections before surgery in women with localised triple-negative breast cancer. With a strong translational research component, the study also investigated immunotherapy's early effects on the tumour and its immune microenvironment, to better understand the mechanisms underlying treatment response.
-
INTERCEPTION: The national pilot program for personalized cancer prevention among individuals at increased risk of cancer enters its operational phase with the enrollment of the first patients
The Interception program has reached a new milestone with the enrollment of its first patients as part of the national Article 51 pilot program. Rolled out over four years across seven healthcare facilities, this pilot program is designed to evaluate an innovative model for personalized cancer prevention and screening.
-
After a breast cancer diagnosis, how can treatment be started more quickly?
Gustave Roussy is launching a new care pathway designed to accelerate the management of women recently diagnosed with breast cancer. It brings together, in a single day, the radiology examinations, blood tests, and oncology consultation required to initiate treatment. This new pathway complements the Institute’s rapid breast care offering. The InstaDiag Breast pathway already consolidates all diagnostic examinations into a single day to establish a diagnosis.
